Characterization of Proliferating Lesion-Resident Cells During All Stages of Atherosclerotic Growth

Sárka Lhoták, PhD;† Gabriel Gyulay, PhD;‡ Jean-Claude Cutz, MD; Ali Al-Hashimi, PhD; Bernardo L. Trigatti, PhD; Carl D. Richards, PhD; Suleiman A. Igdoura, PhD; Gregory R. Steinberg, PhD; Jonathan Bramson, PhD; Kjetil Ask, PhD; Richard C. Austin, PhD

Background—Monocyte recruitment leads to accumulation of macrophage foam cells and contributes to atherosclerotic lesion growth. Recent studies have reported that lesion-resident macrophages can proliferate and represent a major cellular component during lesion development. This study was designed to assess whether the rate of macrophage proliferation changes during well-established stages of lesion growth and to characterize other populations of proliferating cells within these lesions.

Methods and Results—Using murine models of atherosclerosis (Apoe<sup>−/−</sup> and LDLr<sup>−/−</sup> mice) and human coronary artery lesions, in situ proliferation of lesion-resident cells at different stages of growth was assessed by staining for Ki67 and bromodeoxyuridine (BrdU). In early lesions, close to half of all actively growing macrophages were proliferating in situ. BrdU pulse labeling allowed for accurate identification of in situ proliferating macrophages compared to those derived from monocyte recruitment. Local macrophage proliferation declined as lesions advanced. Interestingly, intimal inflammatory cell infiltrates containing proliferating T lymphocytes were identified during the active phase of lesion growth and correlated with apoptotic cell death. Inflammatory cell infiltrates were completely resolved in advanced lesions and replaced with the necrotic core.

Conclusions—Our findings indicate that atherosclerotic lesions contain locally proliferating macrophages primarily during early and intermediate stages of lesion growth. Furthermore, T-lymphocyte-enriched inflammatory cell infiltrates represent a novel subset of proliferating cells within the atherosclerotic lesion that correlate with apoptosis and precede the necrotic core. These findings have novel implications in understanding the pathogenesis of atherosclerosis and may implicate proliferating T lymphocytes as a contributing factor to lesion progression and stability. (J Am Heart Assoc. 2016;5:e003945 doi: 10.1161/JAHA.116.003945)

Key Words: apoptosis • atherosclerosis • cardiovascular disease • lesion • leukocyte • macrophage • proliferation

Cardiovascular disease (CVD) and its associated ischemic events result from thrombus formation superimposed on disrupted atherosclerotic lesions, a process known as atherothrombosis.1 Despite the diversity of cardiovascular risk factors, including genetics, smoking, diabetes mellitus, hypertension, and obesity, the development and progression of atherosclerotic lesions is remarkably comparable.2 Endothelial cell dysfunction as well as the accumulation of cholesterol-rich lipoproteins and expression of proinflammatory factors in the vessel wall are common features of early stages of atherogenesis that result in recruitment of circulating monocytes into the subendothelial space and their differentiation into macrophages.3 The unrestricted uptake and accumulation of lipids in these lesion-resident macrophages eventually leads to formation of foam cells, which enhance lesion growth through secretion of proinflammatory cytokines, cholesterol retention, and apoptosis.4 Although apoptosis is considered a protective event in early atherosclerosis, the capacity for clearance and efferocytosis of resident macrophages decreases as the lesions progress, thus contributing to necrotic core formation in advanced disease.5

The occurrence and conditions that cause macrophage apoptotic cell death at various stages of lesion development remain poorly defined; however, the intricate and dynamic

From the Divisions of Nephrology (Š.L., G.G., A.A.-H., R.C.A.) and Endocrinology (G.R.S.), Department of Medicine and Departments of Pathology and Molecular Medicine (J.-C., C.D.R., J.B.), Biochemistry and Biomedical Sciences (B.L.T., K.A.), and Biology (S.A.I.), McMaster University, Hamilton, Ontario, Canada; Hamilton Centre for Kidney Research, St. Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada (Š.L., G.G., A.A.-H., R.C.A.).

Accompanying Data S1 and Figures S1 through S6 are available at http://jaha.ahajournals.org/content/5/8/e003945/DC1/embed/inline-supplementary-material-1.pdf

*Dr Lhoták and Dr Gyulay contributed equally to this work.

Correspondence to: Richard C. Austin, PhD, McMaster University and the Hamilton Centre for Kidney Research, St. Joseph’s Healthcare Hamilton, 50 Charlton Ave E, Hamilton, Ontario, Canada, L8N 4A6. E-mail: austinr@taari.ca

Received April 27, 2016; accepted July 22, 2016.

© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

DOI: 10.1161/JAHA.116.003945
balance of macrophage death and proliferation is a crucial factor in lesion development and stability.5–8

In addition to recruitment of circulating monocytes, recent work has demonstrated that local macrophage proliferation is a major contributor to lesion growth, especially as atherosclerosis progresses.6,9 However, the relationship between the stage of lesion growth and local macrophage proliferation has not been directly defined.

The concept of local macrophage self-renewal thus provides a new paradigm in understanding the underlying mechanisms that contribute to atherosclerotic lesion growth and stability.7,9–11 Despite this important new discovery, the correlation between macrophage proliferation and plaque growth, as well as the involvement of other proliferating lesion-resident cell types, has not been determined.10,12

The aim of the present study was to utilize mouse models of atherosclerosis and archived tissue derived from atherosclerotic patients to further characterize and identify in situ proliferating lesion-resident cells during all stages of lesion growth. Specifically, we sought to measure whether the rate of macrophage proliferation changes over the course of lesion progression. The use of antigen Ki-67 (Ki67) immunostaining showed the presence of proliferating macrophages within all stages of murine atherosclerotic lesion growth as well as in human coronary artery atherosclerosis. Furthermore, bromodeoxyuridine (Brdu) pulse labeling was used to accurately distinguish locally proliferating macrophages from those derived from circulating monocytes.13 Characterization of locally, or in situ, proliferating macrophages shows their abundance predominantly in early lesions of Apoe−/− mice on a chow diet as well as LDLr−/− mice on a high-fat diet. Close to half of all replicating macrophages were derived from in situ proliferation as opposed to monocyte recruitment.

Furthermore, the local or in situ proliferation of other leukocytes, including T lymphocytes, and their contribution to plaque growth has not been fully characterized, despite the importance of T lymphocytes in atherothrombosis.14–17 Although adventitial inflammatory infiltrates containing T lymphocytes have been previously reported, their occurrence and role in the intima remains poorly defined.18 Our findings demonstrate the presence of transient intimal inflammatory cell infiltrates (ICIs) consisting of proliferating CD3-positive T lymphocytes, which are associated with lesion growth, apoptosis, and a decrease in macrophage proliferation. Our data highlight the diversity and breadth of lesion resident immune cell proliferation during atherogenesis. The balance between leukocyte proliferation and apoptosis is paramount to development of atherosclerotic lesions, and continued delineation of this complex milieu will aid in further understanding the progression of atherothrombosis at the cellular level.

### Methods

#### Animals, Diets, and Reagents

Apoe−/− male and female mice on chow diet, from 8 to 55 weeks old, were sacrificed by cervical dislocation under isoflurane anesthesia. Mice were maintained on a control chow diet, as opposed to a high-fat diet, to reduce the potential confounding effect of obesity and insulin resistance to atherosclerotic lesion development and stability.19 A minimum of 10 Apoe−/− mice were used from each stage of atherosclerosis (as defined by age and lesion characteristics) with 3–5 sections per animal for each immunohistochemical (IHC) analysis. For BrDU pulse labeling, mice were injected with the BrDU Labeling Reagent Ready-to-use (Cat. No. 000103; Invitrogen, Carlsbad, CA), at 1 mL/100 g body weight intraperitoneally, and the heart and small intestine removed at 2 or 24 hours postinjection. LDLr−/− males at 14 weeks of age fed a high-fat diet (42% of calories from fat, 0.2% cholesterol; TD09268; Harlan Teklad, North Easton, MA) for 6 or 8 weeks were also used for IHC analysis. As an accelerated model of diet-induced lesion formation, 10-week-old Apoe−/− mice were made hyperhomocysteinemic by supplementing the drinking water with 0.5% (w/v) L-methionine (Sigma-Aldrich, St. Louis, MO), as described by us previously.20 All procedures were approved by the McMaster University Animal Research Ethics Board. Hearts containing the ascending aorta were dissected, immersion fixed in formalin, and embedded in paraffin. Serial sections (4 μm thick) were cut and collected from the point of the aortic valve, perpendicular to the axis of the aorta, through the aortic root as long as lesions were observed in the microscope in unstained sections.21

#### Immunohistochemical

Sections (4 μm thick) were deparaffinized and the endogenous peroxidase activity blocked with 0.5% H2O2 in methanol for 10 minutes. Antigen retrieval was performed where necessary, sections blocked with 5% normal serum, and incubated with the primary antibody for 1 hour, followed by biotinylated secondary antibody (Vector Laboratories, Burlingame, CA) diluted 1:500, and streptavidin-peroxidase (Vector Laboratories) diluted 1:50. Sections were developed in Nova Red peroxidase substrate (Vector Laboratories) and counterstained with hematoxylin.

#### Immunofluorescence

Sections (4 μm thick) were deparaffinized and antigen retrieval performed, where necessary. After blocking with 5% normal serum, sections were incubated with the first primary antibody for 1 hour, rinsed with Tris buffer,
incubated with the second primary antibody for 1 hour, and rinsed with Tris buffer. A mix of Alexa Fluor (Life Technologies, Carlsbad, CA) 488 and 594 secondary antibodies, each diluted 1:200, was used to incubate sections for 30 minutes. Coverslips were then mounted onto each slide using Permafluor.

Antibodies
Antibodies included anti-BrdU, ab1893 (Abcam, Cambridge, MA), heat-induced epitope retrieval (HIER; pH 6.0), used at 1:500; anti-Ki67, ab16667 (Abcam), HIER, 1:100; anti- Mac-3, #55322 (BD Pharmingen, San Diego, CA), HIER, 1:1000; anti-CD3, A0452 (DakoCytomation, Carpenteria, CA), HIER, 1:100; anti-CD45R, #550286 (Pharmingen), HIER, 1:50; anti-mannose receptor (MR), ab64693 (Abcam), HIER, 1:1000; anti-CD68, clone KP1 (DAKO), HIER, 1:100; anti-CD8, 14-0808 clone 4SM15 (Affymetrix), HIER, 1:50; anti-CD4, 14-9766 clone 4SM95 (Affymetrix, Santa Clara, CA), HIER, 1:200; anti-CD68 (smooth muscle actin), A2547 (Sigma-Aldrich), 1:200; anti-C57BL/6, clone KP1 (DAKO), HIER, 1:100; anti-CD4, 14-9766 clone 4SM95 (Affymetrix, Santa Clara, CA), HIER, 1:100; and anti-CD8, 14-0808 Clone 4SM15 (Affymetrix), HIER, 1:100. Isotype and preimmune negative controls were used during staining optimization and lacked background staining.

Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling Assay
The TACS®2 TdT kit (4810-30-K; Trevigen, Gaithersburg, MD) was used according to the manufacturer’s instructions, followed by immunofluorescence staining.

Human Coronary Arteries
Sections of human coronary arteries were obtained from tissue blocks containing explanted hearts of transplant recipients or cadaver organ donors. All procedures were approved by the McMaster University Research Ethics Board.

Statistical Analysis
Statistical analysis between 2 groups was performed using a Mann–Whitney U test. Error bars represent SEM, unless otherwise noted. Data were considered statistically different if \( P<0.05 \) and demarcated by using an asterisk.

Results
Proliferating Macrophages Are Present at Various Stages of Murine Atherosclerotic Lesion Development and in Human Coronary Artery Atherosclerosis
Paraffin sections of the aortic root from female ApoE\(^{-/-}\) mice at different stages of atherosclerosis were stained with hematoxylin and eosin (H&E) to assess lesion growth and gross cellular morphology (Figure 1A, upper panel). Sections were also stained for Ki67, a well-established marker of active cell division,\(^{22}\) to assess the presence of proliferating cells in these different stages of atherosclerosis (Figure 1A, lower panel). At 8 weeks of age, designated the initial stage, the first intimal macrophages were identified in the subendothelial space. At 12 weeks of age, designated the early lesion group, intimal fatty streaks consisting of lipid-enriched macrophage foam cells were observed. Consistent with these findings, lipid-enriched macrophage foam cells stained intensely for filipin, a marker of free cholesterol, and Oil Red O (ORO), a marker of neutral lipids (Figure S1). This early stage of lesion growth showed no evidence of apoptotic cell death nor the appearance of a lipid-enriched necrotic core, consistent with previous findings.\(^{8}\) At 24 weeks of age, designated the intermediate stage of lesion growth, the intima consisted of a necrotic lipid core with cellular debris and a cellular/fibrous cap. Stretches of simple fatty streaks or individual intimal macrophages were also observed adjacent to these complex lesions (not shown). Filipin and ORO staining was markedly increased in both the necrotic regions and adjacent intact foam cells (Figure S1). At 55 weeks, designated the advanced stage of lesion growth, the lesions were relatively acellular as defined by lack of nuclei, comprised of only a few intact viable cells.

Ki67 is expressed during all active phases of the cell cycle, but is absent in resting cells, and represents a reliable marker for identifying cells that are in the growth cycle.\(^{22}\) A small proportion of intimal cells were Ki67 positive at 8 weeks of age (arrow). Several Ki67-positive cells were observed in the fatty streaks of the early lesion group (arrows), some of which were foam cells by morphology, a result consistent with filipin and ORO staining of lesions (Figure S1). The intermediate group contained some proliferating cells in the cellular/fibrous cap (arrows); however, very few proliferating intimal cells were observed in the advanced stages of lesion growth. Advanced human atherosclerotic plaques from coronary arteries also contained several Ki67-positive cells, both near the lumen (Figure 1B, arrows) and the medial layer (not shown).

To directly identify murine lesion-resident proliferating cells as macrophages, double immunofluorescence of aortic
sections was used to label Mac-3-positive macrophages (green) that expressed Ki67 (red; Figure 2). Ki67-positive macrophages were detected in the lesions of Apoe−/− mice fed a chow diet (Figure 2A) as well as in the lesions of LDLr−/− mice fed a high-fat diet (Figure 2B). The appearance of lipid droplets and the characteristic large, round nuclei further indicates that the Ki67-positive cells from Apoe−/− (Figure 2C) and LDLr−/− mice (Figure 2D) were indeed macrophage foam cells. It is important to note that some proliferating cells were not macrophages, as indicated by positive Ki67 staining in the absence of Mac-3 staining (Figure 2A and 2B, arrows). We also identified lesion-resident proliferating cells as macrophages in human coronary arteries using Ki67 and CD68 immunostaining (Figure 3, upper panel). Immunofluorescent staining showed that Ki67-positive cells are also CD68 positive (Figure 3A through 3D), thus identifying locally proliferating macrophages in human atherosclerosis, consistent with findings by Robbins et al.9 Furthermore, IHC of macrophage-rich areas of human lesions illustrated the presence of Ki67-positive cells (Figure 3E).

Figure 1. Detection of proliferating cells during murine and human atherosclerotic lesion growth. Ki67 immunohistochemistry and H&E staining in Apoe−/− mice on chow diet identified proliferating cells during various stages of lesion progression, ranging from initial macrophage infiltration to advanced lesions (A). In the initial and early stage, macrophages below the endothelium, as well as foam cells in fatty streaks, were Ki67 positive (Initial and Early, arrows). At 24 weeks of age, lesions of the intermediate type with large necrotic cores, few Ki67-positive cells were observed (Intermediate, arrows). At 55 weeks of age, lesions were mostly necrotic with very few Ki67-positive cells (Advanced). Human lesions from coronary arteries stained with Ki67 contained some Ki67-positive cells in areas rich in macrophages (B, arrows). Bar=50 μm. H&E indicates hematoxylin and eosin.

Lesion-Resident Macrophages Proliferate In Situ
To further confirm our Ki67 immunostaining results and to assess the origin of the proliferating cells, a BrdU pulse-labeling experiment was performed in 12-week-old (early lesion group) and 24-week-old (intermediate group) Apoe−/− mice fed a chow diet. BrdU pulse labelling was utilized as a reliable method for identifying in situ proliferation.24 BrdU is incorporated into DNA only during the S phase of the cell cycle and has a half-life of ≈1 hour in the animal.24 Thus, all cells that are in the S phase in the 1-hour window will be labeled, and, once incorporated, BrdU can be detected by IHC in cells that have incorporated it as well as their daughter cells.13 Lesion-resident S-phase cells, as well as proliferating
monocytes derived from the bone marrow and spleen will incorporate BrdU during the pulse. Zhu et al. showed that labeled monocytes can be detected in the bone marrow within 2 hours, and in the blood at 6 hours post-BrdU pulse injection, and that their number in circulation increases and peaks at 12 to 24 hours. Therefore, any BrdU-positive cells 2 hours, and in the blood at 6 hours post-BrdU pulse injection (Figure S2). The intestinal epithelium under-BrdU-stained sections of the jejunum at 2 and 24 hours post-injection (insets), in fatty streaks from ApoE−/− mice (C), and from LDLr−/− mice (D). L, lumen; M, media; bar=50 μm, and 20 μm in high-magnification insets.

Figure 2. Mac-3 and Ki67 immunofluorescence of ApoE−/− and LDLr−/− atherosclerotic lesions detects proliferating macrophages. Double immunofluorescence for the macrophage marker Mac-3 (green) and Ki67 (red) reveals that some of the proliferating cells in the ApoE−/− (A) and LDLr−/− (B) lesions were macrophages. By immunohistochemistry, Ki67-positive cells exhibited foam cell morphology with large nuclei and lipid vesicles visible at high magnification (insets), in fatty streaks from ApoE−/− mice (C), and from LDLr−/− mice (D). L, lumen; M, media; bar=50 μm, and 20 μm in high-magnification insets.

Aortic sections were immunostained for BrdU and Mac-3 and visualized by immunofluorescence. In the early lesion group sacri-fied at 2 hours p.i., the cells in the crypts were positive, and are replaced by cells that proliferate in the crypts and have since traveled through the circulation, extravasated into the intima, and differentiated. This is consistent with the BrdU-stained sections of the jejunum at 2 and 24 hours post-BrdU injection (Figure S2). The intestinal epithelium undergoes turnover as cells are sloughed off from the tips of villi and are replaced by cells that proliferate in the crypts and migrate along the villus. Indeed, in sections from mice sacrificed at 2 hours p.i., the cells in the crypts were positive, whereas at 24 hours p.i., positive cells were only detected further up along the villus (Figure S2).

Aortic sections were immunostained for BrdU and Mac-3 and visualized by immunofluorescence. In the early lesion group sacri-fied at 2 hours p.i. (Figure 4A), some of the Mac-3-positive macrophages were observed to express BrdU, a finding consistent with the positive Ki67 immunostaining (Figure 1B), and confirming that intimal aortic macrophages are proliferating locally, or in situ. No BrdU-positive cells were observed in the lumen of the aorta at this time point. In the early lesion group sacrificed at 24 hours p.i., BrdU-positive monocytes were identified in the lumen, attached to the endothelium, and extravasating through the endothelial layer (Figure 4B, arrows). BrdU-positive cells were also observed in intermediate lesions, some located in the basal portion similar to the 2-hour time point, but mostly located toward the luminal aspect of the lesion (Figure 4C, arrows).

By scoring and comparing BrdU-positive cells at 2 and 24 hours p.i. in aortic sections, the relative contribution of in situ proliferation and of monocyte recruitment into the lesion was determined (Figure 4D through 4I). BrdU-positive macrophages were classified based on their location within the lesion as peripheral (close to the endothelium), internal (deeper in the lesion), or attached (in the lumen attached to the endothelium). The early lesion group consisted of extensive fatty streaks without any morphological evidence of apoptotic cell death (Figure 4D and 4E). The mean total number of BrdU-labeled cells per section was 8.50±1.71 at 24 hours compared to 3.64±0.80 at 2 hours (P=0.022), suggesting that ≈57% of the BrdU-positive cells were derived from the bone marrow (Figure 4F). These data show that 43% of all proliferating cells in early lesions were undergoing proliferation in situ (Figure 4F). No BrdU-positive cells were observed attached to the endothelium at 2 hours p.i. versus 1.37±0.31 cells per section at 24 hours, indicating a lack of blood-derived cells at 2 hours (Figure 4F), as expected. We assumed that BrdU-positive cells found at the luminal aspect of the neointima (peripheral) were mostly cells derived from circulating monocytes within the 24-hour window. Indeed, the total number of peripheral and attached cells was 5.70±0.51 at 24 hours versus 2.08±1.31 at 2 hours (P=0.027) per section. As expected, the number of internal cells was not statistically different between the 2 groups given that these cells most likely represent solely in situ proliferation (Figure 4F). These data indicate that newly arrived cells (internal and peripheral) contribute to the statistically significant difference of total BrdU-positive cells between 24 and 2 hours p.i. in early lesions. In the intermediate lesion group (Figure 4G and 4H), areas of necrosis containing cholesterol crystals were observed. The total number of BrdU-positive cells per section was much less than in the early lesion group despite a larger lesion area (Figure 4I). Upon analyzing intermediate lesions, the total number of BrdU-positive cells per section was 2.10±0.19 versus 1.31±0.40 (P=0.095) in the 24- and 2-hour p.i. groups, respectively (Figure 4I). This suggests a small degree of local proliferation in intermediate lesions as well as a decreased amount of recruited monocytes compared to early lesions. In fact, only 1 BrdU-positive cell was found attached to the endothelium in all 15 sections.
examined (Figure 4H, asterisk), compared to the 17 cells found in the early lesion group, indicating that lesion growth both by in situ macrophage proliferation and monocyte recruitment is considerably reduced in the intermediate lesions from Apoe−/− mice fed a chow diet.

Identification and Characterization of Inflammatory Cell Infiltrates in the Intermediate Stage of Lesion Growth

In addition to the identification of proliferating macrophages, prominent intimal ICIs containing proliferating cells (Figure 5A and 5B) were observed in some sections in the intermediate stage of lesion growth, typically associated with large apoptotic foci. These were not observed in early and advanced lesions. Large ICIs were also present in the adventitia underlying the intimal ICI (Figure 5A, arrowheads), and partially resemble previously described artery tertiary lymphoid organs (ATLOs). Ki67 immunostaining showed that both the intimal and the adventitial ICIs were rich in proliferating cells (Figure 5B), most of which were CD3-positive T lymphocytes (Figure 5C). They also contained macrophages (Mac-3; Figure 5D), but very few smooth muscle cells (SMA; Figure 5E) or neutrophils (MPO; Figure 5F). Interestingly, the ICIs displayed high expression of the M2 markers, YM1 (Figure 5G) and MR (Figure 5H), while having low expression of the M2 marker, Arg 1 (Figure 5I), and the M1 marker, iNOS (Figure 5L). YM1- and MR-positive cells were found solely in the ICIs, as indicated by lack of staining in other parts of the lesions (Figure 5J and 5K, arrows). Taken together, these findings suggest that T-lymphocyte- and macrophage-rich proliferating inflammatory infiltrates occur in the intima of intermediate lesions.

Subsequent to the formation of the necrotic core in advanced lesions, the presence of the ICIs diminished and correlated with few, if any, proliferating cells (Figure 1A and 1B, advanced). Eventually, the ICIs were completely resolved, both in the intima and in the adventitia of the advanced lesions, leaving behind a region containing dead tissue lacking nuclei and containing very few proliferating cells (Figure 1A, advanced). It has been reported that tertiary lymphoid follicles are found in human lesions and in the adventitia of old Apoe−/− mice. To investigate these observations, we utilized IHC to determine whether ICIs represent an acute inflammatory response or lymphoid-like follicles. In contrast to CD3-positive T lymphocytes, the number of adventitial and intimal CD45R-positive B cells was negligible, indicative of an acute inflammatory response in this region (Figure S3). Furthermore, as

Figure 3. CD68- and Ki67-positive macrophages in human coronary artery atherosclerotic lesions. CD68 staining identified proliferating cells (Ki67 positive) in human coronary arteries as macrophages. Double immunofluorescence of Ki67 and CD68 (A through D), a double-labeled cell (Ki67, red; CD68, green), was identified in (A) and magnified in (B). The same cell is shown in separate monochrome images (C and D). Lesion areas rich in macrophages were identified by CD68 immunohistochemistry (E) and then analyzed at higher magnification (F). Adjacent sections were stained with Ki67 (G) and showed that Ki67-positive cells were found in areas rich in macrophages (arrows). Bar=100 μm.
discussed above, the adventitial ICIs are transient in nature and do not exhibit the organized structure of lymphoid follicles. Our findings suggest that these novel lymphocytic aggregates or ICIs represent a transient innate immune reaction rather than organized ectopic lymphoid follicles.

To assess the presence of intimal ICIs during stages of lesion growth and their correlation with apoptosis, H&E-stained sections from female Apoe<sup>−/−</sup> mice fed a chow diet (n=18) were visually examined for gross morphology. At 24 weeks of age, 5 of 18 mice showed the presence of ICIs
Figure 5. Cell-type characterization of inflammatory cell infiltrates (ICIs). Low-magnification hematoxylin and eosin staining delineates the intimal ICI in an intermediate lesion. (A, adventitial infiltrate is marked with arrowheads). Higher magnification consecutive sections of the ICI immunostained for Ki67 (B), T-lymphocyte marker CD3 (C), macrophage marker Mac-3, (D), smooth muscle cell actin (SMA) (E), neutrophil marker myeloperoxidase (MPO) (F), M2 macrophage marker chitinase 3-like 3 (YM1) (G) mannose receptor (MR) (H), and arginase I (Arg I) (I) and M1 macrophage marker inducible nitric oxide synthase (iNOS) (L). YM1- and MR-positive areas are limited to ICIs, both in the intima and adventitia, whereas lesions without the presence of acute inflammation do not express these markers (J and K, arrows). Bar=100 μm.
both in the lesion and the underlying adventitia (Table). Only adventitial ICIs were present in an additional 5 mice. In contrast, 12-week-old female Apoe\(^{-/-}\) mice fed a chow diet (n=15) demonstrated no signs of ICIs or apoptotic cell death. We also reviewed archival slides from a previous study characterizing a methionine model of accelerated lesion formation\(^{20}\) for the presence of ICIs and apoptosis. In 10-week-old female Apoe\(^{-/-}\) mice fed a high methionine diet (n=15), which is known to accelerate lesion growth,\(^{20}\) 14 of 15 mice contained simple fatty streaks without apoptotic nuclei or ICIs. In 1 mouse, ICIs were observed around the apoptotic area and in the underlying adventitia. We believe that this represents the initial onset of apoptosis accompanied by an inflammatory response and formation of the intimal and adventitial ICIs. In addition, ICIs were assessed in 14-week-old male LDLr\(^{-/-}\) mice fed a Western diet for 6 or 8 weeks (n=3 and 7, respectively). After 6 weeks on the diet, lesions were simple fatty streaks with no signs of apoptosis, necrosis, or ICIs. However, LDLr\(^{-/-}\) mice fed a Western diet for 8 weeks presented with some lesions containing apoptotic bodies and cholesterol crystals. At this stage of lesion growth, ICIs were observed in the intima and underlying adventitia in 3 of the 7 mice studied (Figure S4, representative images). These data strongly support the notion that intimal ICIs are transient, exclusive to the intermediate stages of atherosclerosis, and correlate with apoptotic cell death.

Local Proliferation and Recruitment of T Lymphocytes in Inflammatory Cell Infiltrates

BrdU pulse-labeling and CD3 immunostaining was used to assess T-lymphocyte recruitment into the ICIs. At 2 hours post-BrdU pulse, CD3-positive T lymphocytes in the intimal ICI lacked BrdU staining (Figure 6A), implying that the majority of these cells were derived from the circulation. Unlike the intima, BrdU-positive T lymphocytes were observed in the underlying adventitial ICIs (Figure 6A, arrow). Other BrdU-positive cells contained large nuclei and were negative for CD3 (Figure 6A, arrowhead). This suggests that T lymphocytes in intimal ICIs do not proliferate in situ, whereas some T lymphocytes in adventitial ICIs do. At 24 hours p.i., BrdU/CD3-positive T lymphocytes were identified in the intima (Figure 6B, inset, arrow). The location of the BrdU/CD3-positive cells that lie in a single-file pattern along the intimal side of endothelium is suggestive of their recruitment from the aorta. A few BrdU/CD3-positive cells were also observed in the media, suggesting that some of the proliferating T lymphocytes may cross the medial layer, most likely from the adventitia, into the internal part of the lesion (Figure 6B, lower inset, arrow). Overall, these data suggest that T lymphocytes proliferate locally in the adventitial space, whereas intimal ICI resident T lymphocytes accumulate from both the circulation and the adventitia before their active growth cycle.

Inflammatory Cell Infiltrates Are Associated With Apoptosis and Resolve as Lesions Progress

As described previously, during the intermediate stage of lesion growth, intimal ICIs were typically found in regions containing apoptotic cell death, as measured by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)

**Table.** Quantification of ICIs in Mouse Models of Atherosclerosis

<table>
<thead>
<tr>
<th>Strain</th>
<th>Age (weeks)</th>
<th>Diet</th>
<th>Intimal ICIs</th>
<th>Adventitial ICIs</th>
<th>Apoptosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apoe(^{-/-})</td>
<td>24</td>
<td>Chow</td>
<td>5/18</td>
<td>10/18</td>
<td>Yes</td>
</tr>
<tr>
<td>Apoe(^{-/-})</td>
<td>12</td>
<td>Chow</td>
<td>0/15</td>
<td>0/15</td>
<td>No</td>
</tr>
<tr>
<td>Apoe(^{-/-})</td>
<td>10</td>
<td>Methionine</td>
<td>1/15</td>
<td>1/15</td>
<td>Yes (1)</td>
</tr>
<tr>
<td>LDLr(^{-/-})</td>
<td>20</td>
<td>Western 6 weeks</td>
<td>0/3</td>
<td>0/3</td>
<td>No</td>
</tr>
<tr>
<td>LDLr(^{-/-})</td>
<td>22</td>
<td>Western 8 weeks</td>
<td>3/7</td>
<td>3/7</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Quantitative summary of several mouse groups that were scored for presence of intimal ICIs, adventitial ICIs, and apoptosis, showing a strong correlation between apoptosis and ICIs. Ratios depict number of animals exhibiting a certain parameter out of total mice analyzed. Apoe\(^{-/-}\) animals were female and LDLr\(^{-/-}\) animals were male. Five hematoxylin and eosin-stained sections along the aortic sinus, spaced 80 µm apart, were examined from each mouse (n=18 for 24-week chow Apoe\(^{-/-}\), n=15 for 12-week chow Apoe\(^{-/-}\), n=15 for 10-week methionine Apoe\(^{-/-}\), n=3 for 20-week LDLr\(^{-/-}\), and n=7 for 22-week LDLr\(^{-/-}\)). ICIs indicates inflammatory cell infiltrates.

Figure 6. T-cell recruitment into inflammatory cell infiltrates. Double immunofluorescence for CD3 (green) and BrdU (red). Two hours post-BrdU injection, CD3-positive lymphocytes in the intimal inflammatory cell infiltrate (ICI) were BrdU negative (A). BrdU-positive nuclei were present in the adventitial ICI, some in T lymphocytes (arrow, A), and others in macrophages (arrowhead, A). At 24 hours p.i., some of the single-file T lymphocytes lining the endothelium were BrdU positive (arrow, inset, B). Few CD3-positive cells were observed in the media; 1 was BrdU positive (arrow, inset, B), L, lumen; M, media; A, adventitia. Bar=100 µm. BrdU indicates bromodeoxyuridine; p.i., postinjection.

DOI: 10.1161/JAHA.116.003945
staining (Figure 7A). These regions contained apoptotic bodies surrounded by CD3-positive T lymphocytes (Figure 7B) and some macrophages (Figure 7C). In contrast to the intima, large adventitial ICIs contained CD3-positive T lymphocytes with no apoptotic bodies (Figure 7A through 7C). In more-advanced areas of the lesion, proliferation ceases (Figure 7A, box). This area containing apoptotic bodies and cellular debris was found to include macrophages (by Mac-3 staining), but not T lymphocytes (Figure 7A, 7D, and 7E, arrows), suggesting that it is macrophages that undergo apoptosis, rather than T lymphocytes, in this region. This advanced area of the lesion progresses toward a necrotic core, as indicated by its acellular nature and lack of proliferation and ICIs. These data strongly suggest that resolution of ICIs precedes lesion advancement and necrotic core formation.

The different stages of ICI recruitment and necrotic core formation can also be detected in the intermediate stage of a representative complex lesion (Figure 7F and 7G). This diverse lesion includes the early apoptotic stage with proliferating ICIs (Figure 7F-a), the later apoptotic stage where TUNEL-positive apoptotic bodies are present but the acute ICIs have been resolved (Figure 7F-b), and, finally, a necrotic core with the absence of cells/nuclei (Figure 7F-c). These stages of ICI recruitment and necrotic core formation are clearly observed in a consecutive H&E section (Figure 7G). Taken together, these observations suggest that the intimal ICIs may be induced during early apoptosis in the lesion by recruiting inflammatory cells from the aorta and/or the adventitia. This advancing lesion continuum of macrophage proliferation, apoptosis, ICI formation, and resolution and subsequent necrosis is depicted as a model in Figure 8.

**Discussion**

In this report, we demonstrate that in situ macrophage proliferation is prevalent in both murine and human atherosclerosis, with the greatest amount of locally proliferating macrophages occurring in early lesions. Notably, we identify the presence of intimal ICIs enriched with proliferating T lymphocytes in actively growing lesions and show their correlation with apoptosis.

The classical notion that macrophages in lesions are exclusively recruited from circulating monocytes, differentiate terminally, and stop dividing has recently been challenged and addressed extensively.7,12 Interestingly, mitotic activity was reported in foam cells as early as 1948, and despite this process being continuously investigated, only recently has the focus shifted toward fully understanding the proliferative and apoptotic dynamics of macrophages within lesions.4,10,28 By using BrdU and Ki67 staining, the recent study by Robbins et al. demonstrated that macrophage self-renewal contributes significantly to the macrophage population within the lesion.9 Based on these findings, our study was designed to systematically characterize local macrophage proliferation at various

---

DOI: 10.1161/JAHA.116.003945

Journal of the American Heart Association

10

---
Ki67 has been extensively utilized to demonstrate lesion resident macrophage proliferation at various stages of human atherosclerosis, and it enables for accurate detection of cells that are actively proliferating that are not in the G0 phase of the cell cycle. We identified proliferating cells at various stages of lesion development in Apoe−/− mice fed a chow diet, with the predominant amount of cells appearing in the early (12 weeks old) and intermediate (24 weeks old) stages of atherosclerosis. We utilized the Apoe−/− animal model on a chow diet because of its relevance to human disease development and its gradual nature of plaque maturation, enabling us to accurately assess cellular proliferation at distinct stages of lesion progression. Furthermore, we showed the presence of Ki67 proliferating cells in human coronary artery lesions and demonstrated that these proliferating cells are primarily macrophages in both human and murine plaques. This highlights the prevalence of proliferating cells in atherosclerosis and may represent a universal phenomenon among different species. These findings are consistent with those of Robbins et al. and give credence to investigating and characterizing in situ proliferation in our models.

Although Ki67 is a useful, well-characterized marker of cell proliferation, its use in identifying the source of proliferating cells is limited. Alternatively, utilizing a pulse labeling of BrdU allows for accurate identification of the origin of proliferating cells. By comparing BrdU-positive cells at 2 and 24 hours p.i. in aortic sections, we were able to estimate the relative contribution of in situ proliferation and monocyte recruitment into the lesion. In short, any cells that are positive at 2 hours p.i. are considered to have been labeled in situ and are not derived from circulating monocytes. Robbins et al. utilized osmotic pumps that continually saturated cells with BrdU, thus complicating the source of the positively stained proliferating cells, especially given that BrdU is maintained in daughter cells. This method thus allowed us to quantitatively assess the exact contribution of in situ proliferating macrophages and those derived from the circulation and determine that 43% of mitotic macrophages are derived from local proliferation in early lesion development and to identify other lesion-resident proliferating cells and their correlation with apoptosis and plaque progression.

Ki67 has been extensively utilized to demonstrate lesion resident macrophage proliferation at various stages of human atherosclerosis, and it enables for accurate detection of cells that are actively proliferating that are not in the G0 phase of the cell cycle. We identified proliferating cells at various stages of lesion development in Apoe−/− mice fed a chow diet, with the predominant amount of cells appearing in the early (12 weeks old) and intermediate (24 weeks old) stages of atherosclerosis. We utilized the Apoe−/− animal model on a chow diet because of its relevance to human disease development and its gradual nature of plaque maturation, enabling us to accurately assess cellular proliferation at distinct stages of lesion progression. Furthermore, we showed the presence of Ki67 proliferating cells in human coronary artery lesions and demonstrated that these proliferating cells are primarily macrophages in both human and murine plaques. This highlights the prevalence of proliferating cells in atherosclerosis and may represent a universal phenomenon among different species. These findings are consistent with those of Robbins et al. and give credence to investigating and characterizing in situ proliferation in our models.

Although Ki67 is a useful, well-characterized marker of cell proliferation, its use in identifying the source of proliferating cells is limited. Alternatively, utilizing a pulse labeling of BrdU allows for accurate identification of the origin of proliferating cells. By comparing BrdU-positive cells at 2 and 24 hours p.i. in aortic sections, we were able to estimate the relative contribution of in situ proliferation and monocyte recruitment into the lesion. In short, any cells that are positive at 2 hours p.i. are considered to have been labeled in situ and are not derived from circulating monocytes. Robbins et al. utilized osmotic pumps that continually saturated cells with BrdU, thus complicating the source of the positively stained proliferating cells, especially given that BrdU is maintained in daughter cells. This method thus allowed us to quantitatively assess the exact contribution of in situ proliferating macrophages and those derived from the circulation and determine that 43% of mitotic macrophages are derived from local proliferation in early lesion development and to identify other lesion-resident proliferating cells and their correlation with apoptosis and plaque progression.

Ki67 has been extensively utilized to demonstrate lesion resident macrophage proliferation at various stages of human atherosclerosis, and it enables for accurate detection of cells that are actively proliferating that are not in the G0 phase of the cell cycle. We identified proliferating cells at various stages of lesion development in Apoe−/− mice fed a chow diet, with the predominant amount of cells appearing in the early (12 weeks old) and intermediate (24 weeks old) stages of atherosclerosis. We utilized the Apoe−/− animal model on a chow diet because of its relevance to human disease development and its gradual nature of plaque maturation, enabling us to accurately assess cellular proliferation at distinct stages of lesion progression. Furthermore, we showed the presence of Ki67 proliferating cells in human coronary artery lesions and demonstrated that these proliferating cells are primarily macrophages in both human and murine plaques. This highlights the prevalence of proliferating cells in atherosclerosis and may represent a universal phenomenon among different species. These findings are consistent with those of Robbins et al. and give credence to investigating and characterizing in situ proliferation in our models.

Although Ki67 is a useful, well-characterized marker of cell proliferation, its use in identifying the source of proliferating cells is limited. Alternatively, utilizing a pulse labeling of BrdU allows for accurate identification of the origin of proliferating cells. By comparing BrdU-positive cells at 2 and 24 hours p.i. in aortic sections, we were able to estimate the relative contribution of in situ proliferation and monocyte recruitment into the lesion. In short, any cells that are positive at 2 hours p.i. are considered to have been labeled in situ and are not derived from circulating monocytes. Robbins et al. utilized osmotic pumps that continually saturated cells with BrdU, thus complicating the source of the positively stained proliferating cells, especially given that BrdU is maintained in daughter cells. This method thus allowed us to quantitatively assess the exact contribution of in situ proliferating macrophages and those derived from the circulation and determine that 43% of mitotic macrophages are derived from local proliferation in early lesion development and to identify other lesion-resident proliferating cells and their correlation with apoptosis and plaque progression.

Ki67 has been extensively utilized to demonstrate lesion resident macrophage proliferation at various stages of human atherosclerosis, and it enables for accurate detection of cells that are actively proliferating that are not in the G0 phase of the cell cycle. We identified proliferating cells at various stages of lesion development in Apoe−/− mice fed a chow diet, with the predominant amount of cells appearing in the early (12 weeks old) and intermediate (24 weeks old) stages of atherosclerosis. We utilized the Apoe−/− animal model on a chow diet because of its relevance to human disease development and its gradual nature of plaque maturation, enabling us to accurately assess cellular proliferation at distinct stages of lesion progression. Furthermore, we showed the presence of Ki67 proliferating cells in human coronary artery lesions and demonstrated that these proliferating cells are primarily macrophages in both human and murine plaques. This highlights the prevalence of proliferating cells in atherosclerosis and may represent a universal phenomenon among different species. These findings are consistent with those of Robbins et al. and give credence to investigating and characterizing in situ proliferation in our models.

Although Ki67 is a useful, well-characterized marker of cell proliferation, its use in identifying the source of proliferating cells is limited. Alternatively, utilizing a pulse labeling of BrdU allows for accurate identification of the origin of proliferating cells. By comparing BrdU-positive cells at 2 and 24 hours p.i. in aortic sections, we were able to estimate the relative contribution of in situ proliferation and monocyte recruitment into the lesion. In short, any cells that are positive at 2 hours p.i. are considered to have been labeled in situ and are not derived from circulating monocytes. Robbins et al. utilized osmotic pumps that continually saturated cells with BrdU, thus complicating the source of the positively stained proliferating cells, especially given that BrdU is maintained in daughter cells. This method thus allowed us to quantitatively assess the exact contribution of in situ proliferating macrophages and those derived from the circulation and determine that 43% of mitotic macrophages are derived from local proliferation in early lesion development and to identify other lesion-resident proliferating cells and their correlation with apoptosis and plaque progression.

Ki67 has been extensively utilized to demonstrate lesion resident macrophage proliferation at various stages of human atherosclerosis, and it enables for accurate detection of cells that are actively proliferating that are not in the G0 phase of the cell cycle. We identified proliferating cells at various stages of lesion development in Apoe−/− mice fed a chow diet, with the predominant amount of cells appearing in the early (12 weeks old) and intermediate (24 weeks old) stages of atherosclerosis. We utilized the Apoe−/− animal model on a chow diet because of its relevance to human disease development and its gradual nature of plaque maturation, enabling us to accurately assess cellular proliferation at distinct stages of lesion progression. Furthermore, we showed the presence of Ki67 proliferating cells in human coronary artery lesions and demonstrated that these proliferating cells are primarily macrophages in both human and murine plaques. This highlights the prevalence of proliferating cells in atherosclerosis and may represent a universal phenomenon among different species. These findings are consistent with those of Robbins et al. and give credence to investigating and characterizing in situ proliferation in our models.
lesions. Furthermore, using our BrdU method, we showed, both visually and quantitatively, that overall proliferation decreases as lesions advance from an early to intermediate state. This notion differs from other views of in situ macrophage proliferation, which state that local proliferation is predominant at later stages whereas monocyte recruitment is prevalent in early murine atherosclerosis.9,10 Interestingly, Lutgens et al. showed that in humans, DNA synthesis is primarily an early lesion event that slowly halts and gets replaced by apoptosis as lesions advance.35 Our BrdU pulse-labeling proliferation data supports this concept and reinforces our use of ApoE−/− mice on a chow diet in analyzing the dynamics of macrophage proliferation, as opposed to other, more-accelerated diet-induced models of atherosclerosis. It is evident that local macrophage proliferation is a prevalent phenomenon in early atherosclerotic lesions and studying this dynamic cellular biology in more detail would significantly enhance understanding of the disease process as a whole. We therefore also illustrate a technique using Ki67 and BrdU co-immunostaining to accurately identify cell-cycle stages of proliferating macrophages (Figure S5 and Data S1), which can be used to study this process at a greater depth.

Interestingly, we also observed several cells in various lesions that were positive for Ki67, but were not macrophages, a finding that we further investigated. One striking observation was the presence of intimal ICIs in intermediate lesions that contained large cores of proliferative cells. This diverse milieu of proliferating cells represents the first report of cellular proliferation in intimal inflammatory infiltrates of atherosclerotic lesions. To our knowledge, inflammatory infiltrates are usually described as adventitial phenomena, often containing B cells and termed ATLOs.26,33 They have seldom been observed in the intima, with only 1 such report acknowledging them in arteritis of renal allograft patients.34 We determined that these ICIs were comprised primarily of proliferating T lymphocytes and lacked B cells. Proliferation of T lymphocytes has been described in the adventitia with a report addressing the influence of antigen presenting cells and cytokines on this cell subset.27,35 Moreover, though the migration and proinflammatory effects of T lymphocytes in the arterial wall has been explored,17 no study has addressed proliferation of T lymphocytes in the intima or examined defined stages of lesion formation. Our findings visually illustrate the proliferation of intimal T lymphocytes in ICIs and led us to explore the potential functional implications of this unique, albeit transient, phenomenon.

These ICIs were only identified in our gradual onset models of atherosclerosis progression and disappeared in mature lesions, thus pointing to their occurrence being short-lived. In fact, our ability to separate the different stages of atherosclerosis in ApoE−/− mice fed a chow diet allowed us to identify these ICIs, which comprise an important stage of lesion progression. Furthermore, this also enabled the identification of apoptosis adjacent to the ICIs and the observation that ICIs disappeared as lesions advanced and necrotic cores formed. Interestingly, ICIs and apoptotic foci were absent in early lesions and only occurred sporadically in intermediate lesions. This suggests that the acute inflammatory stage containing ICIs is likely to be transient in nature and contains an acute phase of recovery. Nevertheless, we show that T-lymphocyte-enriched ICIs correlate with apoptosis and precede necrosis in lesions upon resolution (Figure 8).

We also sought to characterize the T lymphocytes contained in the ICIs as either cytotoxic/proinflammatory (CD8 positive) or as helper/regulatory cells (CD4 positive).36,37 We identified that the majority of T lymphocytes in intimal ICIs were CD8 and CD4 negative while being CD3 positive (Figure S6), which represent a novel class of T lymphocytes termed double-negative T (DNT) cells.38 DNT cells have been implicated in autoimmune disorders and transplantation immunology with potential roles in apoptosis.38,39 The molecular connection between DNT cells and lesion apoptosis is not known; however, to our knowledge, we are the first to identify DNT cells in atherosclerotic lesions and show they comprise the majority of the ICI.

Overall, our findings strongly suggest that ICIs are induced during the actively growing phase of lesion development and contribute to the process of localized apoptosis within the intimal space, potentially through recruitment of inflammatory cells. As lesions advance, apoptotic cells cannot be cleared as macrophage foam cells lose their ability to phagocytose, thereby further propagating inflammation.6 Necrosis subsequently occurs and results in the formation of necrotic cores,40 with lesion-resident ICIs disappearing before this stage. Figure 7F is a unique example of 3 stages of lesion growth and necrotic core formation occurring simultaneously in 1 section; a—the early apoptotic stage with ICI containing proliferating Ki67-positive cells in the lesion and in the underlying adventitia; b—late apoptotic stage where apoptotic bodies are present but acute inflammation has been resolved; and c—necrotic core with absence of cells/nuclei. This delineates how proliferating T lymphocytes comprising the ICI, and particularly DNT cells, can influence apoptosis and foam cell dynamics as lesions progress. Furthermore, ICIs represent an acute inflammatory event that is rapid and short-lived and may often be missed by histochemical methods. These previously uncharacterized proliferating and biologically active ICIs comprise an important and relevant stage of atherosclerotic growth that may contribute to apoptotic mechanisms and necrosis (Figure 8).

Proliferating atherosclerotic lesion-resident cells remain largely uncharacterized and poorly understood despite their importance in the progression of CVD. We have shown the prevalence and significance of in situ proliferating macrophages
at various stages of murine and human atherosclerotic lesions using Ki67 staining and BrdU pulse-labeling experiments across several models of atherosclerosis. Furthermore, we have identified T-lymphocyte-enriched ICls as a novel transient inflammatory event during active lesion growth. These findings will give rise to a better understanding of human atherosclerosis at the cellular level, particularly with regard to macrophage dynamics, in situ proliferation of leukocytes, as well as apoptosis and necrosis. Overall, this work establishes macrophage and T-lymphocyte self-renewal as a major contributor to lesion growth and stability and as a potential novel therapeutic target for atherosclerosis.

Sources of Funding
This work was supported, in part, by research grants to Richard C. Austin from the Heart and Stroke Foundation of Canada (G-15-0009389), the Canadian Institutes of Health Research (MOP-286787), and a Heart and Stroke Foundation of Ontario Program Grant (PRG6502). Financial support from St. Joseph’s Healthcare Hamilton is acknowledged. Richard C. Austin is a Career Investigator of the Heart and Stroke Foundation of Ontario and holds the Amgen Canada Research Chair in the Division of Nephrology at St. Joseph’s Healthcare and McMaster University.

Disclosures
None.

References


Characterization of Proliferating Lesion–Resident Cells During All Stages of Atherosclerotic Growth

Sárka Lhoták, Gabriel Gyulay, Jean-Claude Cutz, Ali Al-Hashimi, Bernardo L. Trigatti, Carl D. Richards, Suleiman A. Igdoura, Gregory R. Steinberg, Jonathan Bramson, Kjetil Ask and Richard C. Austin

*J Am Heart Assoc.* 2016;5:e003945; originally published August 15, 2016; doi: 10.1161/JAHA.116.003945

The *Journal of the American Heart Association* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://jaha.ahajournals.org/content/5/8/e003945